ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences
ImageneBio, Inc. (IMA)
Company Research
Source: GlobeNewswire
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” “Company”), a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases, including IMG-007, an anti-OX40 monoclonal antibody with multiple differentiating features, today announced management participation in fourth quarter investor conferences. 2025 Stifel Healthcare ConferenceFireside Chat: Thursday, November 13, 9:20am ESTNew York, NY Piper Sander 37th Annual Healthcare ConferenceFireside Chat: Thursday, December 4, 10:00am ESTNew York, NY To access the live webcasts or subsequent archived recordings of the presentation and fireside chat, please visit the ImageneBio IR Site. About ImageneBio, Inc. ImageneBio is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The company’s lead asset,
Show less
Read more
Impact Snapshot
Event Time:
IMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMA alerts
High impacting ImageneBio, Inc. news events
Weekly update
A roundup of the hottest topics
IMA
News
- DISCO Pharmaceuticals Appoints Mark Manfredi as CEO and Announces Final Close of €36 Million Seed Financing [Yahoo! Finance]Yahoo! Finance
- ImageneBio (NASDAQ:IMA) is now covered by analysts at Wedbush. They set an "underperform" rating and a $2.00 price target on the stock.MarketBeat
- ImageneBio (NASDAQ:IMA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team [Yahoo! Finance]Yahoo! Finance
- ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management TeamGlobeNewswire
IMA
Sec Filings
- 1/6/26 - Form SCHEDULE
- 1/2/26 - Form 4
- 12/29/25 - Form 4
- IMA's page on the SEC website